# CORPORATE PROFILE

## **Overview**

ChemBridge<sup>®</sup> Corporation has been a global provider of enabling chemistry products and contract research services for small molecule drug discovery for more than 25 years. Our extensive portfolio includes more than 1.2 million diverse, targeted and focused screening compounds, more than 6,000 synthetic macrocycles, more than 14,000 chemical building blocks, our Hit2Lead.com online chemical store, and high-end, research-intensive custom library and synthetic/medicinal chemistry services.

ChemBridge has provided over 30 million screening compounds and building blocks to hundreds of pharmaceutical, biotechnology, academic and non-profit organizations worldwide. These compounds support small molecule discovery and development programs in industry and have enabled many scientific discoveries in academia, as featured in over 1,800 scientific articles in leading research journals. Our track record of success as a discovery chemistry CRO includes major multi-year research collaborations with leading pharmaceutical companies. ChemBridge is a privately held US company founded by Eugene Vaisberg, Sergey Altshteyn and Gala Vaisberg in 1993. Since 1997 ChemBridge has been headquartered in San Diego where sales, marketing, customer support, and administration are located. ChemBridge has a European sales representative based in the United Kingdom and distributors in Japan, China, and Korea. Our offshore chemistry research and order packaging site is in Moscow, Russia. The Moscow research team includes synthetic and analytical chemists and a cheminformatics group.

### Screening Compounds

ChemBridge has been a provider of high quality screening compounds and libraries for more than 25 years and continues to produce novel, druglike and leadlike screening compounds based on the evolving requirements of drug discovery and chemical biology researchers in industry and academia. We currently offer more than 1.2 million druglike and leadlike screening compounds and more than 6,000 synthetic macrocycles that are readily available from stock. Clients can custom select compounds from our stock or can choose from our pre-plated diversity sets or targeted and focused selections created using compounds from our stock.

# Macrocycles

ChemBridge recently introduced the Macrocycle Library compounds, a new library of more than 6,000 synthetic, macrocyclic compounds. The use of synthetic macrocycles is becoming a well-recognized approach for low druggability targets such as antimicrobial, antiviral, and protein-protein interaction inhibition. Researchers can custom select compounds from the Macrocycle Library or purchase the full set.

## Building Blocks

Our building block collection, consisting of more than 14,000 products, has been developed to support medicinal chemists working on advanced hit-to-lead, lead generation, and lead optimization programs. All of our chemical building blocks undergo extensive quality control by NMR and LC-MS, and purity is guaranteed to be over 95%. Our chemical building blocks are listed in all major third-party databases and are available for on-line purchase via ChemBridge's Hit2Lead.com online chemical store. All building blocks are available from stock and the majority are available for RUSH delivery from our San Diego facility.

### Chemistry Services

ChemBridge provides research, development, and production of custom chemical libraries on an exclusive basis for its partners. Our platform matches the most challenging quality standards of the world's leading pharmaceutical companies and enables us to deliver custom chemical libraries within our partners' demanding timelines. ChemBridge also has more than a decade of experience synthesizing exclusive building blocks and scaffolds. Libraries and compounds are synthesized to the client's specifications and analytical requirements under fee-for-service and FTE based models.

© 2018 ChemBridge Corp. All rights reserved. ChemBridge and DIVERSet are trademarks registered in the US Patent and Trademark Office belonging to ChemBridge Corp. Rev. 20180828